Regardless of their treatment assignment in the parent study , patients were randomized 2:1 to receive either open-label subcutaneous evolocumab 420 mg every 4 weeks with standard of care ( SOC ) ( evolocumab + SOC , n = 736 ) or SOC alone ( n = 368 ) .